当前位置: 首页 > 详情页

Normobaric Oxygen May Ameliorate Cerebral Venous Outflow Disturbance-Related Neurological Symptoms

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China, [2]Department of Neurology, TianjinMedical University General Hospital, Tianjin, China, [3]Epilepsy Center, Beijing Fengtai You’anmen Hospital, Beijing, China, [4]Department of Neurology, Tianjin Huanhu Hospital, Tianjin, China, [5]Advanced Center of Stroke, Beijing Institute for BrainDisorders, Beijing, China, [6]Department of China-America Institute of Neuroscience, Xuanwu Hospital, Capital MedicalUniversity, Beijing, China, [7]Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI,United States, [8]Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China
出处:
ISSN:

关键词: normobaric oxygen cerebral venous outflow disturbance brain dysfunction EEG neurological impairment

摘要:
Cerebral venous outflow disturbance (CVOD) has begun to garner the attention of researches owing to a series of clinical symptoms that impose a significant impact on people's quality of life. Herein, we aimed to investigate whether normobaric oxygen (NBO) can ameliorate CVOD-induced neurological symptoms. This was one part of the prospective trial registered in (NCT03373292). A total of 37 CVOD patients were divided into the NBO group (5-8 L/min of oxygen inhalation, 1 h per time, 3 times daily, n = 19) and the control group (without oxygen inhalation, n = 18) randomly. The assessments were performed at admission, 1-week hospitalization, and 6-month follow-up. Quantitative electroencephalogram (qEEG) data were recorded prior to and post 1 h of NBO in some patients. R software was used for data analysis. No NBO-related adverse events were observed during the whole NBO intervention process. The 1-week Patient Global Impression of Change (PGIC) scale showed that the symptom improvement occurred in nine patients in the NBO group (47.4%) while none in the control group (p = 0.001). NBO could improve headache evaluated with visual analog scale (pre-NBO vs. post-NBO: 4.70 +/- 2.16 vs. 2.90 +/- 2.03, p = 0.024) and Headache Impact Test-6 (53.40 +/- 12.15 vs. 50.30 +/- 13.04, p = 0.041). As for 6-month PGIC follow-up, eight out of 14 cases (57.1%) in the NBO group reported improvement, while only one out of 12 patients in the control group replied mild improvement (p = 0.014). The qEEG revealed that NBO reduced the ratio of theta to alpha power (0.65 +/- 0.38 vs. 0.56 +/- 0.35, p = 0.030) over the fronto-central electrodes. To sum up, NBO may be a safe and effective approach to attenuate CVOD-related symptoms (especially for headache) by brain functional improvement resulting from increasing oxygen supply to the brain tissues.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 3 区 医学
小类 | 3 区 临床神经病学 3 区 神经科学
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 临床神经病学 3 区 神经科学
JCR分区:
出版当年[2018]版:
Q3 CLINICAL NEUROLOGY Q3 NEUROSCIENCES
最新[2023]版:
Q2 CLINICAL NEUROLOGY Q3 NEUROSCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China, [2]Department of Neurology, TianjinMedical University General Hospital, Tianjin, China,
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院